Published on 23/12/2025
Improving Patient Diversity in Clinical Trials in China: Achievements and Challenges
Introduction
Patient diversity in clinical trials is critical to ensuring that therapies are safe and effective across different populations. In China, with its vast population of over 1.4 billion people and wide demographic variability, the importance of inclusion cannot be overstated. Historically, most clinical trials in China recruited patients from Tier-1 hospitals in urban areas, creating gaps in representation for rural populations, elderly patients, ethnic minorities, and certain disease subgroups. The National Medical Products Administration (NMPA) has recently emphasized the need for broader inclusion, aligning with International Council for Harmonisation (ICH) E17 guidance on multinational clinical trials. While progress has been made in expanding access, significant gaps remain in patient diversity within Chinese clinical research. This article explores the current landscape, regulatory expectations, and strategies to close diversity gaps in Chinese trials.
Background and Regulatory Framework
Historic Urban-Centric Recruitment
For decades, Chinese clinical trials were concentrated in Tier-1 hospitals in cities like Beijing and Shanghai. These institutions offered advanced infrastructure and experienced investigators but limited the geographic and demographic scope of enrolled patients. This urban-centric model left rural populations and ethnic minorities underrepresented.
NMPA’s Role
Since 2017, China’s membership in ICH has prompted reforms to align with global diversity expectations. The NMPA now encourages sponsors to expand recruitment beyond Tier-1 hospitals, emphasizing patient inclusion from diverse age groups, genders, and regions. Ethical guidelines also require equitable access to trial opportunities.
Case Example: Rural Recruitment Pilot
A diabetes trial in Hunan province successfully expanded recruitment to Tier-2 hospitals serving rural populations. With CRO support and tailored informed consent materials, the trial achieved greater representation of elderly and rural patients, improving the generalizability of results.
Core Clinical Trial Insights
Demographic Gaps in Representation
Despite reforms, patient diversity gaps remain. Trials in China often underrepresent:
✔️ Elderly patients, despite China’s rapidly aging population
✔️ Women in oncology and cardiovascular studies
✔️ Ethnic minorities, particularly in western provinces
✔️ Pediatric patients, especially in rare disease research
Addressing these gaps is crucial for regulatory approval and ethical trial conduct.
Barriers to Diverse Recruitment
Challenges to diversity include:
✔️ Limited infrastructure in rural hospitals
✔️ Language barriers for minority populations
✔️ Lack of disease registries for rare conditions
✔️ Cultural mistrust of clinical research
✔️ High competition for patients in Tier-1 hospitals
These factors often skew recruitment toward urban, younger, and male-dominated populations.
Role of Ethics Committees
Ethics committees in China are responsible for ensuring equitable recruitment. However, many committees lack standardized approaches to assessing diversity in protocols. The NMPA is piloting centralized ethics reviews that emphasize inclusion and diversity metrics in trial designs.
Impact on Multinational Trials
For multinational clinical trials (MRCTs), inadequate representation of Chinese subpopulations can hinder global submissions. Regulators such as the FDA and EMA increasingly require evidence of diverse participation. Including diverse Chinese patients strengthens global data acceptance and reduces the need for bridging studies.
Patient Advocacy and Community Engagement
Patient advocacy organizations are playing a larger role in encouraging trial participation from underrepresented groups, particularly in oncology and rare diseases. Sponsors are increasingly collaborating with advocacy groups to build trust and awareness among patients.
Decentralized and Digital Trial Models
Digital health tools, including eConsent and telemedicine, are helping bridge geographic gaps by enabling rural and home-based participation. While still in early stages, decentralized trial models are expected to expand access to diverse patient populations in China.
Best Practices & Preventive Measures
Sponsors should integrate diversity goals into trial design, selecting sites beyond Tier-1 hospitals and adapting informed consent materials for local languages and literacy levels. CRO partnerships can support rural recruitment, while decentralized trial models can reduce participation burdens. Patient advocacy engagement should be embedded into recruitment strategies to build trust and ensure ethical inclusivity.
Scientific & Regulatory Evidence
China’s approach to diversity aligns with ICH E17 MRCT guidelines, which emphasize subgroup representation across regions. WHO GCP and the Declaration of Helsinki further mandate equitable access to trials. Comparative evidence shows that increased diversity improves external validity, making results more generalizable to the wider patient population.
Special Considerations
Special attention is needed for pediatric, elderly, and minority populations in China. For example, pharmacokinetics may differ in elderly patients, requiring dedicated subgroup analyses. Language adaptations for ethnic minorities, including Tibetan and Uighur populations, are necessary to ensure informed consent and ethical compliance.
When Sponsors Should Seek Regulatory Advice
Sponsors should engage the NMPA early when trial designs involve underrepresented groups. Regulatory advice helps clarify expectations for subgroup representation and data analysis. Sponsors should also consult ethics committees when planning recruitment strategies for rural or minority populations to ensure compliance and ethical oversight.
Case Studies
Case Study 1: Oncology Trial Expanding Diversity
A multinational oncology sponsor expanded recruitment to Tier-2 hospitals in western provinces to include ethnic minority patients. With CRO support and multilingual consent materials, the trial achieved improved demographic diversity, enhancing global data acceptance.
Case Study 2: Rare Disease Trial and Advocacy Partnerships
A rare disease trial partnered with a Chinese patient advocacy organization to identify pediatric patients across rural areas. This collaboration increased enrollment diversity and highlighted the importance of advocacy partnerships in addressing recruitment gaps.
FAQs
1. Why is patient diversity important in Chinese trials?
Diverse participation ensures that trial results reflect the safety and efficacy of therapies across different demographic and regional groups.
2. Which populations are underrepresented in Chinese trials?
Elderly patients, women, pediatric populations, and ethnic minorities remain underrepresented in many therapeutic areas.
3. How does the NMPA address diversity?
The NMPA encourages broader site selection, requires equitable recruitment practices, and is piloting centralized ethics reviews that emphasize inclusion.
4. Can decentralized trials improve diversity?
Yes, digital tools and telemedicine can expand access for rural and underserved populations, reducing participation barriers.
5. What role do advocacy groups play in diversity?
They build trust, raise awareness, and connect sponsors with underrepresented patients, especially in oncology and rare disease trials.
6. How does diversity affect multinational trial acceptance?
Better representation of Chinese subpopulations strengthens global data acceptance and reduces the need for bridging studies.
Conclusion & Call-to-Action
China has made progress in improving patient diversity in clinical trials, but gaps remain in representing elderly, pediatric, rural, and minority populations. Sponsors must proactively design trials that include diverse patients, engage advocacy groups, and leverage digital tools to reduce participation barriers. Organizations planning trials in China should integrate diversity strategies into feasibility and regulatory planning to ensure both compliance and ethical inclusivity. Addressing diversity is not only a regulatory requirement but also an ethical obligation to ensure equitable access to innovation.